LTZ Therapeutics Inc. has completed a series A financing of more than $20 million to advance the development of its myeloid engager pipeline to treat cancer and autoimmune diseases. The closing of this round brings LTZ’s total funding to about $50 million.
Gigagen Inc., a subsidiary of Grifols SA, has received clearance from the FDA of its IND application to conduct a phase I trial of GIGA-2339 for the treatment of hepatitis B virus (HBV) infections.
A study on the posttranslational modification through lactylation of non-histone proteins revealed a mechanism that participates in genome stability and provides resistance to chemotherapy. Scientists from The Second and The Seventh Affiliated Hospital of Sun Yat-sen University (SYSU) identified the lactation of the Nijmegen breakage syndrome 1 (NBS1) protein and the enzymes that participate in this process as a strategic point in cancer therapy.
Ensho Therapeutics Inc. launched in July after licensing a pipeline of four oral α4β7 inhibitors for inflammatory and gastrointestinal disorders, including inflammatory bowel disease (IBD), from EA Pharma Co. Ltd. “Millions of people worldwide are living with IBD,” Ensho founder, president and executive chair Neena Bitritto-Garg recently told BioWorld, “and while there are a number of approved medications to address the symptoms of IBD, it remains a difficult-to-treat disease with high relapse rates for a considerable proportion of patients.”
Kodiak Sciences Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of age-related macular degeneration, choroidal neovascularization, diabetic macular edema, dry eye, glaucoma, bacterial keratitis, retinitis and uveitis, among others.
Apellis Pharmaceuticals Inc. has identified C3 convertase inhibitors reported to be useful for the treatment of cancer, obesity, infections, neurological disorders, autoimmune and inflammatory disorders, age-related macular degeneration and chronic obstructive pulmonary disease (COPD), among others.
Recombination Therapeutics LLC and Thomas Jefferson University have synthesized DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
RSS
